Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) gapped up before the market opened on Friday . The stock had previously closed at $8.50, but opened at $9.17. Recursion Pharmaceuticals shares last traded at $9.73, with a volume of 31,013,556 shares trading hands.
Wall Street Analysts Forecast Growth
RXRX has been the topic of a number of analyst reports. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Thursday, February 6th. KeyCorp lowered their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th.
Read Our Latest Analysis on Recursion Pharmaceuticals
Recursion Pharmaceuticals Trading Up 2.2 %
The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a 50 day simple moving average of $7.38 and a 200-day simple moving average of $6.95. The firm has a market cap of $4.25 billion, a P/E ratio of -7.10 and a beta of 0.86.
Institutional Trading of Recursion Pharmaceuticals
Large investors have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC bought a new stake in Recursion Pharmaceuticals in the 3rd quarter worth approximately $25,000. Decker Retirement Planning Inc. bought a new stake in Recursion Pharmaceuticals in the 4th quarter worth approximately $26,000. Private Trust Co. NA bought a new stake in Recursion Pharmaceuticals in the 4th quarter worth approximately $27,000. GAMMA Investing LLC increased its stake in Recursion Pharmaceuticals by 1,979.2% in the 4th quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock worth $35,000 after acquiring an additional 4,948 shares during the last quarter. Finally, Farther Finance Advisors LLC increased its stake in Recursion Pharmaceuticals by 176.9% in the 3rd quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock worth $42,000 after acquiring an additional 4,091 shares during the last quarter. Institutional investors own 89.06% of the company's stock.
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
See Also
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
